


N-linked Intact Glycopeptides Proteomics Overview



Service Description


Glycosylation modification plays an important role in the formation of protein function and structure. Over half of the proteins present in living organisms undergo glycosylation modification. Glycosylated proteins are involved in various phenomena like cell adhesion, molecular recognition, and signal transduction. N-linked glycosylation is a prevalent and essential type of protein glycosylation modification. Precisely characterizing N-linked glycosylation is valuable for discovering disease biomarkers and potential therapeutic targets, as well as developing effective vaccines against various viruses.

The structural analysis of site-specific glycans remains challenging due to the complexity of glycan structures and the heterogeneity of glycosylation. We provide an N-linked intact glycopeptide analysis to determine detailed N-glycan structures at the site-specific level by using the StrucGP[1], which was published in Nature Methods in 2021 and is the first software to distinguish different structure isoforms within the same glycan composition and identify new glycan structures. In addition, N-linked intact glycopeptides can be accurately quantified using isobaric label quantitative proteomics service.



The complexity of glycan structures and the heterogeneity of glycosylation

Workflow



N-LINKED INTACT GLYCOPEPTIDES PROTEOMICS OVERVIEW

Advantages

Interprets precise glycan structures and identifies new/rare glycans without relying on glycan database.

Simultaneously obtains the glycan chain structure, glycosylation-modified peptide, and the relationship between the glycan chain and the glycosylation site.

Identifies over 5,000 glycopeptides for conventional full-spectrum identification and over 14000 for ultra-deep detection.

TMT (Tandem Mass Tags for Quantitation)/IBT (Isobaric Tags for Quantitation) analysis can simultaneously compare 18 different samples.

Research Applications

Disease biomarker research


Molecular typing research

Molecular mechanism research


Growth and development research

Biologics characterization

Results




N-LINKED INTACT GLYCOPEPTIDES PROTEOMICS OVERVIEW




Glycan structures and glycosylation sites heat map




Identified glycan structures




Distributions and abundances of special monosaccharides



Distributions of four core structures



Distributions of three glycan subtypes



Distributions and abundances of branch structures identified

General Sample Requirements

Sample Type		Sample Amount	
		Recommended	Minimum
Animal	Common animal tissues: animal internal organs (heart, liver, spleen, lung, kidney), skin, muscle, brain, etc.	≥ 100 mg	≥ 50 mg
	Mollusks (Toxoplasma, Schistosomiasis, Drosophila, Acarid, Plutella xylostella, Laodelphax, Cestode, Cicada, Hematodinium, etc.)	≥ 100 mg	≥ 50 mg
Cell	Suspended cells, adherent cells	≥ 1x10 ⁸	≥ 5x10 ⁷
Protein Solution	Complex protein solution, protein powder	≥ 5 mg	≥ 3 mg
	Single protein (purified protein solution by IP, CO-IP, etc.)	30 μg	20 μg
Liquid	Serum and plasma	500 μL	300 μL
	Body fluid	2 mL	1 mL

Turn Around Time

Typical 4-5 weeks from sample QC acceptance to data report delivery

Reference

[1] StrucGP: de novo structural sequencing of site-specific N-glycan on glycoproteins using a modularization strategy. *Nat Methods*.2021



Request for Information or Quotation

Contact a BGI Genomics representative to discuss how we can meet your specific needs or for expert advice on experiment design, from sample to bioinformatics.

info@bgi.com
www.bgi.com

For Research Use Only. Not for use in diagnostic procedures (except as specifically noted).

Copyright© BGI Genomics 2025. All trademarks are the property of BGI Genomics or their respective owners. This material contains information on products targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information, which may not comply with any legal process, regulation, registration, or usage in the country of your origin. Unless otherwise informed, certain sequencers and sequencing reagents are not available in selected countries or regions. Please get in touch with a representative for regional availability. The company reserves the right of final interpretation.



www.bgi.com



BGI Genomics

